How Bordetella Pertussis Adapts to Human Nasal Tissue to Evade Immune Defenses
Bordetella pertussis can rewire its virulence machinery inside human nasal tissue, shifting toward biofilm-associated growth while damping the host defenses that normally clear it, according to a study on the pathogen’s adaptation to the human nasal mucosa.
Work on the whooping cough bacterium matters because it explains why a strictly human disease keeps resurging despite widespread vaccination.
- A study reports that Bordetella pertussis adapts to human nasal mucosa by reprogramming toward biofilm-associated virulence and attenuating host-defense responses.
- The bacterium’s established immune-evasion toolkit includes blocking neutrophil traffic, suppressing phagocyte activation, triggering cell death, and blocking complement-mediated killing.
Why the nasal mucosa is the battleground
The finding addresses a long-standing gap in pertussis pathogenesis: how the bacterium establishes infection in the nose, the first site of human exposure, before descending to the lower airway. The researchers grew B. pertussis with primary human nasal epithelial cultures — tissue donated through the Comprehensive Transplant Center Human Tissue Biorepository at The Ohio State University Wexner Medical Center or Nationwide Children’s Hospital, per the study’s funding and resource disclosures.
Those cultures came from the Cure Cystic Fibrosis Columbus (C3) Epithelial Cell Core at Nationwide Children’s Hospital and Ohio State, which exists to give researchers access to real human airway tissue rather than simplified cell lines. Per the study, the bacterium uses that interface to adopt a biofilm-associated virulence program while blunting the epithelial and innate immune signals that would otherwise recruit reinforcements.
The delay that lets whooping cough take hold
The new biofilm findings fit a well-documented pattern of immune subversion in this pathogen. A peer-reviewed review of B. pertussis pathogenicity and its adaptation to its human host catalogs four core strategies: inhibiting cell traffic to the respiratory tract, suppressing phagocyte activation, triggering cell death, and blocking complement-mediated killing.
The clearest illustration is a signaling delay. Neutrophil recruitment pathways fire within 6 hours of infection in mice, yet the neutrophils themselves reach the lungs up to 3 days late. Pertussis toxin drives that gap, the review states, by choking off the chemokine production that TLR-4 activation in alveolar macrophages — and likely epithelial cells — would otherwise generate. Those are the chemokines that attract the very cells meant to clear the airway.
Once phagocytes arrive, the organism still interferes. The adenylate cyclase toxin can stop primary human monocytes from differentiating into fully phagocytic macrophages, and it can de-differentiate alveolar macrophages into monocyte-like cells that kill bacteria less efficiently. The review notes this reprogramming might be particularly relevant to infection of infants and the elderly, whose immune defense relies strongly on innate immunity, with monocytes and macrophages providing protection.
What the biofilm shift adds
Where the earlier work mapped how B. pertussis disarms circulating defenses, the study describes the bacterium adjusting its own program to the nasal environment: virulence reprogramming tied to biofilm formation, alongside attenuation of host-defense responses.
A biofilm state is a different survival strategy than the free-swimming, toxin-dominant mode that pertussis vaccines largely target. That distinction matters to anyone expecting next-generation vaccine design, because antigens selected against one growth state may underperform against the other.
For clinicians, the practical read is unchanged for now. Pertussis remains a reportable vaccine-preventable disease managed with standard antimicrobial therapy; the study explains mechanisms, and no new therapy follows from it yet.
Who paid for the work
The funding picture, disclosed in the study, points to federal and philanthropic support. H.W. is supported by R35 GM152205, and A.F. by a Burroughs Wellcome Fund Investigators in the Pathogenesis of Infectious Diseases award, an American Lung Association award, and NIGMS grant R35 GM150806.
MM is supported in part by an institutional T32 predoctoral fellowship and an American Heart Association predoctoral fellowship, and HMS was supported in part by The Ohio State University Clinical and Translational Science Institute and the National Center for Advancing Translational Sciences under a grant.
The cystic fibrosis core that supplied nasal cultures runs on a Research Development Program grant from the Cystic Fibrosis Foundation and multiple NIH awards to investigator M.E.P., including R01 AI185617, P01 AI112524, P01 AI175399, R01 AI093848, R21 AI180667, U19 AI42733, and CFFT PEEPLE25XX0. Tissue came from the Ohio State transplant center biorepository or the children’s hospital, with work also aided by an intramural microscopy core.
Where the science goes from here
The reporting frames the biofilm-associated reprogramming in human nasal mucosa as a step toward understanding how B. pertussis survives its strictly human host across the infection cycle — adherence, immune evasion, and persistence in one tissue after another.
What the study does not resolve is how biofilm-state bacteria respond to standard antimicrobial therapy in vivo, and whether the virulence program seen in nasal epithelium predicts what happens deeper in the airway. The pathogen’s own record on that front is sobering: the neutrophil delay alone buys it roughly three days of protected growth in the lung before the earliest infantry arrives.
The vaccination schedule remains the standard of care for preventing whooping cough. Families managing recurrent or prolonged cough illness can ask their physician about pertussis testing and vaccine timing, and laboratory confirmation typically runs through diagnostic respiratory panels at accredited clinical laboratories.
The nasal tissue used in the study was donated through the Comprehensive Transplant Center at The Ohio State University Wexner Medical Center, a multidisciplinary academic medical center on the university’s main campus in Columbus, Ohio. The complex was renamed in 2012 after Les Wexner, then-chair of the university’s Board of Trustees, who donated $100 million to the university and championed fundraising for its construction.
Today the medical center cares for more than 62,000 inpatients annually and manages more than 1.86 million outpatient visits each year, with a workforce of more than 23,000 employees, including more than 2,000 physicians. Its newest University Hospital, a 26-story tower with more than 800 beds, officially opened in February 2026.
Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.